Phagemid for antibody screening

US6730483B2 · kind B2 · utility

Assignee

• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE

Inventors

• Frank Breitling · Heidelberg, DE
• Melvyn Little · Büdelsdorf, DE
• Stefan Dubel · Dossenheim, DE
• Michael Braunagel · Oslo, NO
• Iris Klewinghaus · Mannheim, DE

Key dates

• Filing date: Apr 8, 2002
• Grant date: May 4, 2004
• Expiry date: Apr 8, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2795/10322
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.